ENDRA Life Sciences Inc (NDRA) - Cash Flow Conversion Efficiency
Based on the latest financial reports, ENDRA Life Sciences Inc (NDRA) has a cash flow conversion efficiency ratio of -0.147x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-927.56K) by net assets ($6.31 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see ENDRA Life Sciences Inc market cap and net worth for the company's overall valuation and market capitalisation.
ENDRA Life Sciences Inc - Cash Flow Conversion Efficiency Trend (2014–2025)
This chart illustrates how ENDRA Life Sciences Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
ENDRA Life Sciences Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of ENDRA Life Sciences Inc ranked by their cash flow conversion efficiency. Explore ENDRA Life Sciences Inc (NDRA) cash flow quality to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
WISDOM ED.INTL.HLD.HD-01
F:5Q4
|
N/A |
|
Baillie Gifford Japan Trust
LSE:BGFD
|
0.003x |
|
K2 Asset Management Holdings Ltd
AU:KAM
|
0.052x |
|
Celsius Resources Limited
F:FX8
|
-0.046x |
|
FingerMotion Inc
NASDAQ:FNGR
|
-0.176x |
|
Synex International Inc.
TO:SXI
|
0.061x |
|
Morella Corporation Ltd
AU:1MC
|
-0.082x |
|
Dongyang S.Tec Co.Ltd
KQ:060380
|
0.012x |
Annual Cash Flow Conversion Efficiency for ENDRA Life Sciences Inc (2014–2025)
The table below shows the annual cash flow conversion efficiency of ENDRA Life Sciences Inc from 2014 to 2025. View ENDRA Life Sciences Inc (NDRA) stock price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $2.26 Million | $-5.18 Million | -2.293x | +20.67% |
| 2024-12-31 | $2.56 Million | $-7.40 Million | -2.890x | -71.30% |
| 2023-12-31 | $5.66 Million | $-9.55 Million | -1.687x | +4.80% |
| 2022-12-31 | $7.20 Million | $-12.77 Million | -1.772x | -71.85% |
| 2021-12-31 | $10.78 Million | $-11.12 Million | -1.031x | +31.35% |
| 2020-12-31 | $7.17 Million | $-10.77 Million | -1.502x | +16.73% |
| 2019-12-31 | $4.76 Million | $-8.59 Million | -1.804x | -46.35% |
| 2018-12-31 | $6.25 Million | $-7.70 Million | -1.233x | -97.02% |
| 2017-12-31 | $5.28 Million | $-3.30 Million | -0.626x | -142.51% |
| 2016-12-31 | $-893.77K | $-1.32 Million | 1.472x | +143.72% |
| 2015-12-31 | $250.30K | $-842.73K | -3.367x | -45.87% |
| 2014-12-31 | $605.33K | $-1.40 Million | -2.308x | -- |
About ENDRA Life Sciences Inc
ENDRA Life Sciences Inc. develops technologies to improve the capabilities of clinical diagnostic ultrasound. The company is involved in the development of thermo-acoustic enhanced ultrasound technology that uses pulsed energy source such as radio frequency to transmit energy deep into tissue and generate ultrasonic waves to create high-contrast images for use in the treatment of non-alcoholic fa… Read more